ANNX logo

Annexon Inc. (ANNX)

$3.47

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on ANNX

Market cap

$661951024

EPS

-1.02

P/E ratio

--

Price to sales

--

Dividend yield

--

Beta

1.437152

Price on ANNX

Previous close

$3.57

Today's open

$3.57

Day's range

$3.37 - $3.67

52 week range

$2.67 - $7.18

Profile about ANNX

CEO

Douglas Love

Employees

92

Headquarters

Brisbane, CA

Exchange

Nasdaq Global Select

Shares outstanding

190763984

Issue type

Common Stock

ANNX industries and sectors

Healthcare

Biotechnology & Life Sciences

News on ANNX

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to a new non-executive employee under the terms of the 2022 Employment Inducement Award Plan.

news source

GlobeNewsWire • 19 hours ago

news preview

Annexon Reports Third Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones

Differentiated C1q Platform Advances Two Registrational Programs with Blockbuster Potential, Driving Near-Term Value Catalysts  Tanruprubart U.S./EU FORWARD Data in GBS Strengthens BLA Submission Package Anticipated in Q4 2026; Tanruprubart EU MAA Currently Under Review Vonaprument ARCHER II Phase 3 Well-Designed to Demonstrate Clinically Meaningful Vision Protection in GA; Month 15 Primary Endpoint Assessment on Track for Q4 2026 ANX1502 Data Support Continued Development of Potential First Oral C1s Inhibitor for Autoimmune Diseases, including gMG; Tablet Formulation Optimization Underway Cash, Cash Equivalents and Short-Term Investments of $213 Million as of September 30, 2026, Provide Anticipated Runway into 2028 BRISBANE, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX) a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact approximately 10 million people worldwide, today highlighted portfolio progress, announced key anticipated milestones, and reported third quarter 2026 financial results.

news source

GlobeNewsWire • Nov 9, 2026

news preview

Annexon Eyes Q4 2026 Phase III Readout for Vision-Preserving GA Drug

Annexon NASDAQ: ANNX said it expects to report the month-15 primary-endpoint analysis from its Phase III ARCHER II trial of vonaprument in geographic atrophy, or GA, during the fourth quarter of 2026. The company is testing the C1q-targeting treatment with vision preservation, rather than lesion growth, as its primary efficacy focus.

news source

MarketBeat • Nov 4, 2026

news preview

Annexon, Inc. (ANNX) Discusses Vonaprument Phase III ARCHER II Trial in Geographic Atrophy Transcript

Annexon, Inc. (ANNX) Discusses Vonaprument Phase III ARCHER II Trial in Geographic Atrophy Transcript

news source

Seeking Alpha • Nov 3, 2026

news preview

Annexon to Host Virtual Investor Event on November 3, 2026: Vonaprument for the Treatment of Geographic Atrophy - Highlighting Key Aspects of Phase 3 ARCHER II Trial

BRISBANE, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it will host a virtual investor event on Tuesday, November 3, 2026 at 11:00 AM ET regarding the ARCHER II Phase 3 program.

news source

GlobeNewsWire • Oct 28, 2026

news preview

Annexon: Preserving Patient Function Is The Real Investment Opportunity

Annexon targets functional patient outcomes in geographic atrophy and Guillain-Barré syndrome, aiming for clinical differentiation via vision and physical recovery preservation. ANNX maintains a cash runway into 2028, supported by $209.2M in liquidity and a $200M Oxford Finance facility, but future financing remains a risk. The ARCHER II trial pivots to functional vision endpoints, with key readouts expected in Q4 2026 and potential market expansion if vision preservation is confirmed.

news source

Seeking Alpha • Sep 27, 2026

news preview

Annexon to Present Patient Baseline Characteristics from Vonaprument Phase 3 ARCHER II Pivotal Trial for Geographic Atrophy at The Retina Society 59th Annual Scientific Meeting

Oral Presentations Highlight Phase 2 Vision Protection and Enrollment of a Consistent Phase 3 Patient Population Well-Positioned to Replicate Phase 2 Vision Outcomes ARCHER II is the First Pivotal Trial Designed to Demonstrate Protection of Vision in Geographic Atrophy, with Month 15 Results Expected in the Fourth Quarter of 2026 BRISBANE, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced two oral presentations on vonaprument at The Retina Society 59th Annual Scientific Meeting being held September 23-26, 2026 in Los Angeles, California.

news source

GlobeNewsWire • Sep 24, 2026

news preview

Annexon to Participate in Upcoming September Investor Conferences

BRISBANE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that Douglas Love, Esq., president & chief executive officer, will participate in fireside chats during the following September investor conferences:

news source

GlobeNewsWire • Sep 2, 2026

news preview

Annexon Q2 Earnings Call Highlights

Annexon NASDAQ: ANNX said it expanded its pivotal ARCHER II trial of vonaprument in geographic atrophy, adding an independent 24-month dual primary endpoint alongside the study's existing 15-month primary endpoint. The company said it remains confident in a planned fourth-quarter assessment of the 15-month endpoint while seeking to capture longer-term efficacy data for a potential product label.

news source

MarketBeat • Aug 12, 2026

news preview

Annexon, Inc. (ANNX) Q2 2026 Earnings Call Transcript

Annexon, Inc. (ANNX) Q2 2026 Earnings Call Transcript

news source

Seeking Alpha • Aug 12, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Annexon Inc.

Open an M1 investment account to buy and sell Annexon Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in ANNX on M1